Gene therapy approval and Regeneron's rare disease win headline biotech updates
The FDA has approved a gene therapy from Ultragenyx, marking a significant regulatory milestone. Additionally, Regeneron secured approval for a drug targeting an ultra-rare condition, and the news highlights progress in mRNA-based research.
Related stories
Regeneron secures approval for ultra-rare bone disorder drug · Drug development
Regeneron wins FDA approval for first treatment of rare bone-forming disease · Drug development
J&J's Imaavy becomes first approved therapy for rare anemia · Drug development
This summary is AI-generated and original to Mobble; the linked article is the authoritative source.
Original headline: “STAT+: FDA approves Ultragenyx gene therapy.” Browse more stories.